Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/8737
Cohort profile: the MCC-Spain follow-up on colorectal, breast and prostate cancers: study design and initial results
Alonso-Molero, Jessica | Molina, Antonio J | Jiménez-Moleón, Jose Juan | Perez-Gomez, Beatriz ISCIII | Martin, Vicente | Moreno, Victor | Amiano, Pilar | Ardanaz, Eva | de Sanjose, Silvia | Salcedo, Inmaculada | Fernandez-Tardon, Guillermo | Alguacil, Juan | Salas, Dolores | Marcos-Gragera, Rafael | Chirlaque, Maria Dolores | Aragones, Nuria ISCIII | Castaño-Vinyals, Gemma | Pollan-Santamaria, Marina ISCIII | Kogevinas, Manolis | Llorca, Javier
BMJ Open. 2019 Nov 21;9(11):e031904.
PURPOSE: Since 2016, the multicase-control study in Spain (MCC-Spain) has focused towards the identification of factors associated with cancer prognosis. Inception cohorts of patients with colorectal, breast and prostate cancers were assembled using the incident cases originally recruited. PARTICIPANTS: 2140 new cases of colorectal cancer, 1732 of breast cancer and 1112 of prostate cancer were initially recruited in 12 Spanish provinces; all cancers were incident and pathologically confirmed. Follow-up was obtained for 2097 (98%), 1685 (97%) and 1055 (94.9%) patients, respectively. FINDINGS TO DATE: Information gathered at recruitment included sociodemographic factors, medical history, lifestyle and environmental exposures. Biological samples were obtained, and 80% of patients were genotyped using a commercial exome array. The follow-up was performed by (1) reviewing medical records; (2) interviewing the patients by phone on quality of life; and (3) verifying vital status and cause of death in the Spanish National Death Index. Ninety-seven per cent of recruited patients were successfully followed up in 2017 or 2018; patient-years of follow-up were 30 914. Most colorectal cancers (52%) were at clinical stage II or lower at recruitment; 819 patients died in the follow-up and the 5-year survival was better for women (74.4%) than men (70.0%). 71% of breast cancers were diagnosed at stages I or II; 206 women with breast cancer died in the follow-up and the 5-year survival was 90.7%. 49% of prostate cancers were diagnosed at stage II and 32% at stage III; 119 patients with prostate cancer died in the follow-up and the 5-year survival was 93.7%. FUTURE PLANS: MCC-Spain has built three prospective cohorts on highly frequent cancers across Spain, allowing to investigate socioeconomic, clinical, lifestyle, environmental and genetic variables as putative prognosis factors determining survival of patients of the three cancers and the inter-relationship of these factors.
Files in this item